Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Medy Tox Inc (086900 KS)
Watchlist
66
Analysis
Health Care
•
South Korea
Medy-Tox Inc. is a biopharmaceutical company. The Company researches, develops and manufactures biopharmaceutical products using clostridium botulinum which is a microorganism toxin.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
01 Aug 2016 15:19
Alpha Generation & Share Buybacks in Korea
Korean companies are showing increasing willingness to buyback shares. Korea Stock Exchange announced that from beginning of this year to as of 27...
Douglas Kim
Follow
689 Views
Share
bullish
•
Thematic (Sector/Industry)
•
07 Jul 2016 00:13
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
Sanghyun Park
Follow
3.6k Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Jul 2016 09:24
What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....
If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...
Douglas Kim
Follow
469 Views
Share
bullish
•
Thematic (Sector/Industry)
•
29 Feb 2016 14:39
Share Buybacks in Korea - Top 9 Insights
In this report, we highlight 39 companies that have announced share buybacks in the past three months (Dec 2015 - Feb 2016) in Korea. We provide...
Douglas Kim
Follow
446 Views
Share
bullish
•
Thematic (Sector/Industry)
•
16 Feb 2016 00:59
2016 Major IPOs Pipeline in Korea - Part II
In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...
Douglas Kim
Follow
404 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x